Cargando…
Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase
The mechanisms underlying anaplastic lymphoma kinase (ALK) resistance have not been well investigated in clinical practice. We herein report the case of a lung cancer patient with carcinomatous meningitis who had an ALK I1171T resistance mutation revealed by direct DNA sequencing of the cerebrospina...
Autores principales: | Ashinuma, Hironori, Shingyoji, Masato, Hasegawa, Yuzo, Yokoi, Sana, Yoshida, Yasushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6262718/ https://www.ncbi.nlm.nih.gov/pubmed/29877262 http://dx.doi.org/10.2169/internalmedicine.0397-17 |
Ejemplares similares
-
A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer
por: Ashinuma, Hironori, et al.
Publicado: (2019) -
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021) -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018) -
An unusual presentation of carcinomatous meningitis
por: Foo, Chuan T., et al.
Publicado: (2016) -
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)